A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

This study is testing a combination of two targeted cancer drugs — emavusertib and a BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib) — in patients with chronic lymphocytic leukemia (CLL) or other B-cell blood cancers whose disease has not fully responded to a BTK inhibitor alone. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of CLL or another B-cell cancer - You have been on a BTK inhibitor but still have measurable disease remaining - You are in reasonably good health (able to carry out daily activities) - Your life expectancy is at least 3 months **You may NOT be eligible if...** - Your cancer has progressed rapidly on a BTK inhibitor (rather than having residual stable disease) - You have severe organ dysfunction - You have an active serious infection - You are pregnant or breastfeeding - You have significant heart problems including recent heart attack Talk to your doctor to see if this trial is right for you.